1. Home
  2. TYRA vs RBCAA Comparison

TYRA vs RBCAA Comparison

Compare TYRA & RBCAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TYRA
  • RBCAA
  • Stock Information
  • Founded
  • TYRA 2018
  • RBCAA 1974
  • Country
  • TYRA United States
  • RBCAA United States
  • Employees
  • TYRA N/A
  • RBCAA N/A
  • Industry
  • TYRA Biotechnology: Pharmaceutical Preparations
  • RBCAA Major Banks
  • Sector
  • TYRA Health Care
  • RBCAA Finance
  • Exchange
  • TYRA Nasdaq
  • RBCAA Nasdaq
  • Market Cap
  • TYRA 812.7M
  • RBCAA 1.5B
  • IPO Year
  • TYRA 2021
  • RBCAA 1998
  • Fundamental
  • Price
  • TYRA $14.43
  • RBCAA $68.99
  • Analyst Decision
  • TYRA Strong Buy
  • RBCAA
  • Analyst Count
  • TYRA 5
  • RBCAA 0
  • Target Price
  • TYRA $31.00
  • RBCAA N/A
  • AVG Volume (30 Days)
  • TYRA 201.5K
  • RBCAA 18.9K
  • Earning Date
  • TYRA 11-07-2024
  • RBCAA 01-24-2025
  • Dividend Yield
  • TYRA N/A
  • RBCAA 2.38%
  • EPS Growth
  • TYRA N/A
  • RBCAA 15.67
  • EPS
  • TYRA N/A
  • RBCAA 5.18
  • Revenue
  • TYRA N/A
  • RBCAA $324,440,000.00
  • Revenue This Year
  • TYRA N/A
  • RBCAA N/A
  • Revenue Next Year
  • TYRA N/A
  • RBCAA $4.24
  • P/E Ratio
  • TYRA N/A
  • RBCAA $13.23
  • Revenue Growth
  • TYRA N/A
  • RBCAA 5.10
  • 52 Week Low
  • TYRA $11.24
  • RBCAA $46.55
  • 52 Week High
  • TYRA $29.60
  • RBCAA $80.68
  • Technical
  • Relative Strength Index (RSI)
  • TYRA 42.39
  • RBCAA 34.91
  • Support Level
  • TYRA $13.27
  • RBCAA $69.06
  • Resistance Level
  • TYRA $14.77
  • RBCAA $71.87
  • Average True Range (ATR)
  • TYRA 0.75
  • RBCAA 2.36
  • MACD
  • TYRA 0.07
  • RBCAA -0.63
  • Stochastic Oscillator
  • TYRA 50.19
  • RBCAA 9.59

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).

About RBCAA Republic Bancorp Inc.

Republic Bancorp Inc operates as a financial institution that provides both traditional and non-traditional banking products through six reportable segments. It has traditional banking which generates the majority of revenue, warehouse, mortgage banking, Tax Refund Solutions (TRS), Republic Payment Solutions segment, and Republic Credit Solutions (RCS) business segments. The business activities of these segments include retail mortgage and commercial lending, construction and land development lending, internet lending, correspondent and indirect lending and also private banking, treasury management services, internet, and mobile banking, bank acquisitions, short-term revolving credit facilities, fixed-term residential real estate loans and receipt and payment of federal.

Share on Social Networks: